Table 3

Immunological response in subjects who received AstraZeneca

Withhold therapyContinue therapyControlsTotal
Detectable SARS-CoV2 Ab*
Post first vaccine dose21/31 (67.7)9/33 (27.3)19/24 (79.2)49/88 (55.68)
 Withhold versus continue (p=0.002)
 Withhold versus controls (p=0.380)
 Continue versus controls (p=0.000)
Post second vaccine dose27/27 (100)36/43 (83.7)22/22 (100)85/92 (92.39)
 Withhold versus continue (p=0.038)
 Withhold versus controls
 Continue versus controls (p=0.000)
Mean SARS-CoV2 Ab titre†
Post first vaccine dose2.17 (2.32)1.25 (1.58)6.50 (11.47)3.00 (6.51)
 Withhold versus continue (p=0.014)1.4 (2.7)0.5 (0.6)2.1 (5.05)0.95 (2.25)
 Withhold versus controls (p=0.105)
 Continue versus controls (p=0.000)
Post second vaccine dose26.55 (33.00)14.70 (22.73)13.10 (11.53)17.79 (24.76)
 Withhold versus continue (p=0.086)7.7 (46.5)4.9 (18.1)10.6 (13.2)6.5 (19.9)
 Withhold versus controls (p=0.709)
 Continue versus controls (p=0.119)
  • Data are presented as proportions (%) or mean (SD) and median (IQR).

  • *Using Fisher’s exact test with significance cut-off 5%.

  • †Using Wilcoxon-Mann-Whitney U test with significance cut-off 5%.

  • Ab, antibody.